- Home
- Companies
- usa oklahoma
- genome editing
Show results for
Refine by
Genome Editing Suppliers Serving Usa Oklahoma
26 companies found
based inCambridge, MASSACHUSETTS (USA)
Editas Medicine is a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for people living with serious diseases around ...
Genomic medicine is a developing field of medical research that harnesses recent advances in genetics to develop new medicines for diseases. In fact, we are at an inflection point where we are seeing the first real ...
based inSeattle, WASHINGTON (USA)
Universal Cells is a Seattle-based company that is producing engineered stem cell lines that can avoid rejection and be used in allogeneic cell therapy treatments for the people who need them. One Cell, Many Therapies. Universal Cells edits genes ...
Universal Cells uses recombinant Adeno-Associated Virus (rAAV)-mediated gene editing to engineer chromosomal genes without the use of genotoxic nucleases. Serotype 3B rAAV vectors efficiently infect pluripotent stem cells and their ...
based inCambridge, MASSACHUSETTS (USA)
Abcam identifies, develops, and provides high-quality biological reagents and tools which are essential in a wide range of fields and applications including drug discovery, diagnostics and basic research. We supply the global life science community ...
based inEugene, OREGON (USA)
InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. An expert in CRISPR genome ...
Knockouts are the bread and butter of reverse genetic studies. They allow researchers to study the effects of the absence of a particular gene, protein segment, amino acid, or regulatory element, thereby enabling the researcher to determine their ...
based in, NEW YORK (USA)
'Creative BioMart provides quality recombinant proteins, diagnostic antibodies and antigens, diagnostic enzymes and pharmaceutical enzymes to the research community of biology, clinical research, molecular diagnostics and biopharmaceutical drug ...
based inBerkeley, CALIFORNIA (USA)
Indee Labs is developing a non-viral, intracellular delivery system based on microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene editing complexes with minimal perturbation. The technology is used by global ...
Hydropore™ is a simple, scalable and efficient way to accelerate the discovery, development and manufacturing of gene-modified cell therapies (GMCTs) such as T cell immunotherapies. This novel, non-viral technology utilizes the ...
based inCoralville, IOWA (USA)
A champion of life sciences research for more than 30 years, IDT develops and manufactures nucleic acid products that support the life sciences industry. Areas of focus include academic and commercial research, agriculture, medical diagnostics, ...
The Alt-R CRISPR-Cas9 System includes all of the reagents needed for successful genome editing based on the natural S. pyogenes CRISPR-Cas9 system. Discover what makes the Alt-R CRISPR-Cas9 system best in ...
based inPalo Alto, CALIFORNIA (USA)
SBI is a small biotech company that’s delivered innovative products and services for molecular and cell biology research since January 2004, when we sold our first lentivectors and pPACK lentivirus packaging systems. We focus on being the first ...
Use this first-generation SBI EF1α-hspCas9 SmartNickase when you want to reduce off-target events, have transfectable cells, and prefer an intact vector. Conveniently deliver Cas9 Nickase and gRNA with a single vector. Reduce off-target ...
based inMilpitas, CALIFORNIA (USA)
ASC Therapeutics is a fully incorporated biopharmaceutical company focusing on the development of curative therapeutic products that are enabled by our proprietary gene editing platform, TARGATT and other gene editing technologies developed after 12 ...
Genome editing technologies enables permanent modifications to the genome by harnessing the activities of certain enzymes (e.g. nucleases and integrase) and invoking DNA repair mechanisms at ...
based inMenlo Park,, CALIFORNIA (USA)
Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. Based on a foundation of engineering and chemistry, Synthego leverages automation and machine ...
based inBrisbane, CALIFORNIA (USA)
Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. ...
Enhanced genome editing with an expanded CRISPR toolkit: Our CRISPR-Cas systems provide unprecedented power to edit the ...
based inShirley, NEW YORK (USA)
Creative Biogene provides kits, reagents, and services that help researchers explore questions about gene discovery, regulation, and function. Creative Biogene holds a leadership position in the global market and is committed to improving the human ...
CRISPR/Cas9 technology has been used as a genome-editing tool for multiple cell lines, such as tumor cell line and embryonic stem cell lines. Primary T cell, as an important class of immune cells system, play an ...
based inWageningen, NETHERLANDS
KeyGene is the go-to global research company for the development and application of breakthrough technology to improve a wide variety of crops. We help our partners solve their toughest R&D challenges by discovering, understanding and using genetic ...
Finding new ways to improve crops by developing and using cell and tissue technology in plant breeding. Innovations in cell and tissue culture technology provide exciting new opportunities to improve crops, particularly those that are difficult to ...
based inBerkeley, CALIFORNIA (USA)
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell ...
We are developing differentiated, off-the-shelf CAR-T cell therapies, derived from healthy donor T cells, that are genome-edited to improve persistence of antitumor activity and potential therapeutic benefit. ...
based inAthens, GEORGIA (US) (USA)
Athens Research & Technology Inc. has been purifying human proteins and developing polyclonal antisera to those proteins since 1986. We specialize in highly pure, highly active human proteins. We routinely purify serine proteases, protease ...
based inGlattbrugg, SWITZERLAND
Since 2009, Cytosurge AG develops, manufactures, and distributes state-of-the-art nanotechnology solutions and systems based on its patented FluidFM® technology. At the heart of the technology are the hollow FluidFM Probes, which have apertures down ...
Custom CRISPR cell line engineering service based on our FluidFM® ...
based inEmeryville, CALIFORNIA (USA)
Metagenomi is a biotechnology company at the forefront of genetic engineering, striving to leverage microbial evolution to develop groundbreaking therapies for diseases. The company employs metagenomics, the study of genetic material recovered ...
Genomic replacements and insertions; Metagenomi’s RIGS make programmable genomic modifications that are encoded in RNA templates. Using RIGS we can ...
based inWashington, DISTRICT OF COLUMBIA (USA)
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory, reimbursement and ...
based inMadison, WISCONSIN (USA)
Mirus continued the development of a wide range of non-viral delivery technologies using proteins, polymers, and lipids in conjunction with novel chemistries that provided unique nucleic acid delivery capabilities. Our work at Mirus Bio began with a ...
based inCambridge, MASSACHUSETTS (USA)
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with ...
We plan to initiate patient screening for a first-in-human Phase 1 study of NTLA-5001, a WT1-directed TCR T cell therapy for the treatment of AML, by the end of 2021. Our first ex vivo development candidate seeks to treat acute myeloid leukemia ...